Abstract
Nowadays it is possible to use several drugs of etiotropic therapy with different mechanisms of action and different costs for the treatment of COVID-19. Purpose was to study the costs of antiviral drugs in the infectious hospital of the Volgograd region and perform cost-minimization analyse of one course of antiviral therapy. Materials and methods. ABC analysis was carried out on the basis of reporting and accounting documentation for the issuance of drugs for 2020–2022. Ihe prices of the State Register of Maximum Selling Prices were used in cost-minimization analyse. Results. In 2020, 2021 and 2022 6; 2,7 and 10,6 % of the total costs for drugs, respectively, were spent on antiviral drugs. Among such drugs as favipiravir, molnupiravir, nirmatrelvir/ritonavir and remdesivir, molnupiravir of some manufacturers had the lowest cost of 1 course of therapy, and remdesivir had the highest cost.
Publisher
Volgograd State Medical University
Subject
Anesthesiology and Pain Medicine